Cocrystal Pharma (NASDAQ:COCP) Shares Down 2.1% – Here’s Why

Cocrystal Pharma, Inc. (NASDAQ:COCP) fell 2.1% during mid-day trading on Monday . The stock traded as low as $0.93 and last traded at $0.93. 16,486 shares changed hands during mid-day trading, a decline of 63% from the average session volume of 44,991 shares. The stock had previously closed at $0.95.

Analyst Ratings Changes

Separately, Weiss Ratings upgraded Cocrystal Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, June 8th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, Cocrystal Pharma currently has a consensus rating of “Sell”.

Cocrystal Pharma Price Performance

The company has a market cap of $12.84 million, a price-to-earnings ratio of -1.28 and a beta of 1.41. The company’s 50-day simple moving average is $1.05 and its 200-day simple moving average is $1.11.

Cocrystal Pharma (NASDAQ:COCP) last posted its earnings results on Friday, May 15th. The company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.02). The firm had revenue of $0.23 million for the quarter, compared to analyst estimates of $0.23 million. Equities analysts predict that Cocrystal Pharma, Inc. will post -0.69 EPS for the current fiscal year.

Hedge Funds Weigh In On Cocrystal Pharma

A hedge fund recently bought a new stake in Cocrystal Pharma stock. DRW Securities LLC bought a new position in shares of Cocrystal Pharma, Inc. (NASDAQ:COCP) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 33,593 shares of the company’s stock, valued at approximately $33,000. DRW Securities LLC owned about 0.24% of Cocrystal Pharma as of its most recent filing with the Securities and Exchange Commission (SEC). 6.72% of the stock is owned by hedge funds and other institutional investors.

About Cocrystal Pharma

Cocrystal Pharma, Inc (NASDAQ:COCP) is a clinical-stage biotechnology company focused on the discovery and development of novel antiviral therapeutics. Utilizing an integrated structure-guided drug design platform, the company combines x-ray crystallography, computational chemistry and medicinal chemistry to identify and optimize small molecule inhibitors targeting key viral enzymes. This approach is intended to accelerate the progression of lead candidates from discovery through preclinical development.

The company’s pipeline includes multiple preclinical programs aimed at treating respiratory and systemic viral infections.